BC Week In Review | Jun 16, 2014
Clinical News

DNIB0600A: Additional Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 38 evaluable NSCLC or platinum-resistant ovarian cancer patients with immunohistochemistry (IHC) scores of 2/3+ for tumor NaPi2b expression showed that 2.4 mg/kg IV DNIB0600A every 3 weeks...
BC Week In Review | Jun 3, 2013
Clinical News

DNIB0600A: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 18 evaluable patients with non-squamous NSCLC or platinum-resistant ovarian cancer showed that 1.8-2.8 mg/kg doses of IV DNIB0600A given every 3 weeks led to 3 confirmed partial...
Items per page:
1 - 2 of 2